CYTK · Cytokinetics, Incorporated
$73.88
+0.35% last session
End-of-day data · close of 2026-09-11
Market cap
$10B
Enterprise value
$10B
Trailing P/E
—
Forward P/E
-16.5
Dividend yield
—
Beta
0.36
Avg volume
2M
Employees
1K
Daily Change %
0.35%
5 Days Change
1.91%
10 Days Change
4.51%
30 Days Change
-3.06%
60 Days Change
-12.68%
Month to Day Change
3.80%
Year to Day Change
16.64%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CYTK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-31
Latest call per bank · past 12 months
Barclays
Overweight$110
+49.4% vs priceJP Morgan
Overweight$103
+39.9% vs priceRBC Capital
Outperform$112
+52.1% vs priceUBS
Buy$115
+56.2% vs priceCitigroup
Buy$99.00
+34.5% vs priceWells Fargo
Overweight$105
+42.6% vs priceMorgan Stanley
Overweight$103
+39.9% vs priceGoldman Sachs
Buy$95.00
+29.0% vs priceBank of America
Neutral$56.00
-23.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-31 | HC Wainwright & Co. | Reiterates | Buy | $140 |
| 2026-08-13 | Barclays | Maintains | Overweight | $95.00 → $110 |
| 2026-08-13 | JP Morgan | Maintains | Overweight | $97.00 → $103 |
| 2026-08-10 | Truist Securities | Maintains | Buy | $106 → $112 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $117 → $112 |
| 2026-08-07 | Citizens | Maintains | Market Outperform | $105 → $110 |
| 2026-08-07 | Needham | Maintains | Buy | $102 → $112 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $119 → $117 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.7% below the 50-day MA ($78.33).
- Price vs 200-day MA: Trading 5.6% above the 200-day MA ($69.95).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.08) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($47.56) and high ($87.26).
CYTK Price Chart
Loading chart for CYTK…
Fundamentals
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.